Published September 9, 2013
| Accepted Version
Journal Article
Open
Use of a palladium(II)-catalyzed oxidative kinetic resolution in synthetic efforts toward bielschowskysin
Chicago
Abstract
Progress toward the cyclobutane core of bielshowskysin is reported. The core was thought to arise from a cyclopropane intermediate via a furan-mediated cyclopropane fragmentation, followed by a 1,4-Michael addition. The synthesis of the cyclopropane intermediate utilizes a Suzuki coupling reaction, an esterification with 2-diazoacetoacetic acid, and a copper catalyzed cyclopropanation. An alcohol intermediate within the synthetic route was obtained in high enantiopurity via a highly selective palladium(II)-catalyzed oxidative kinetic resolution (OKR).
Additional Information
© 2013 Elsevier Ltd. Received 18 December 2012; Received in revised form 8 February 2013; Accepted 8 February 2013; Available online 19 February 2013. The authors are grateful to the NIH-NIGMS (R01GM080269), the Bristol-Myers Squibb Company (predoctoral fellowship to E.M.F.), California Institute of Technology, A. P. Sloan Foundation, the Dreyfus Foundation, Research Corporation, Abbott (d), Amgen, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Johnson and Johnson, Eli Lilly, Merck, Novartis, Pfizer, and Roche for generous funding.Attached Files
Accepted Version - nihms447820.pdf
Files
nihms447820.pdf
Files
(4.8 MB)
Name | Size | Download all |
---|---|---|
md5:f66bcbee7f2a6f816bddb73925fa207c
|
4.8 MB | Preview Download |
Additional details
- PMCID
- PMC3728638
- Eprint ID
- 41655
- Resolver ID
- CaltechAUTHORS:20131003-103642590
- NIH
- R01GM080269
- Bristol-Myers Squibb Company
- Caltech
- Alfred P. Sloan Foundation
- Camille and Henry Dreyfus Foundation
- Research Corporation
- Abbott
- Amgen
- AstraZeneca
- Boehringer-Ingelheim
- GlaxoSmithKline
- Johnson and Johnson
- Eli Lilly
- Merck
- Novartis
- Pfizer
- Roche
- Created
-
2013-10-03Created from EPrint's datestamp field
- Updated
-
2021-11-10Created from EPrint's last_modified field